USBIOTICS® Antibiotic/Antiviral Design

USBIOTICS® is on a mission to discover novel Antibiotics and Antivirals which treat highly resistant bacterial and viral strains.  Our research focuses on analogs which demonstrate excellent activity against targeted pathogens with multi-drug resistant phenotypes and developing antibacterial and antiviral agents that target cellular envelope, block protein production and/or target RNA dependent RNA polymerase RdRp.

  • Drug Discovery – Macrolides with beta-lactam inhibitor combos  / Novel seventh generation cephalosporin derivatives.

  • Homeland Security – USBIOTICS® is building Anti-Chemical/Biological Warfare Agents (Anti-CBW Agents) for our US Homeland.  The greatest threat to America in the 21st century are biological weapons and over 18 countries possess this technology.  The US Homeland demands countermeasure anti-chemical/biological warfare agents to protect citizens from this imminent national security threat.

Development of an arsenal of analog derivatives, Anti-CBW cocktails and combinations designed to be active against stubbornly resistant bacterial and viral strains.  Targeting new analogs and inhibitor combinations which have shown marked enhancement against most aerobic Gram-positive bacteria, aerobic Gram-negative, anaerobic bacteria and inhibitors of engineered viruses with novel antiviral cocktails.

Our approach

Research

Currently under research: Multi-generation Cephalosporins and Vancomycin pro-drugs

CONTACT US

Discovery

Pro-drug delivery systems – in vivo conversion based on penicillin G, ceftriaxone, and ampicillins.

ABOUT OUR APPROACH

Analysis

We are additionally interested in pro-drugs that select for C. difficile bacteria resistance.

DATA-DRIVEN SOLUTIONS

Testing

ESBL strains are often resistant to non-beta-lactam antibiotics pro-drugs effective against this resistance.

FIND OUT MORE

USBIOTICS® is a multi-disciplinary Biopharmaceutical firm focused on developing Novel Anti-CBW Agents

Contact Us